Roche received FDA clearance for a molecular vaginitis test targeting bacterial vaginosis and Candida vaginitis from clinician-collected or self-collected vaginal swabs. The assay clearance expands Roche’s footprint in women’s health diagnostics, aligning testing workflows with patient-access preferences that increasingly favor at-home collection. The test uses swabs to detect organisms associated with BV and CV, supporting clinical decision-making for targeted treatment rather than symptom-based prescribing. The clearance also emphasizes the shift toward lab-validated molecular diagnostics with scalable sample logistics. For biotech and med-tech partners, the approval signals ongoing regulatory openness to self-collection models paired with molecular detection—an area with strong implications for turnaround times and care-delivery design.